Neoplastic Process – Page 4

Spotlight On: Five key oncology stories to watch in 2026

3 weeks ago talkbio0Tagged 2026, Antibody-Drug Conjugates, cancer research trends, CAR-T, Cell Therapy, Liquid Biopsy, Lymphocytes, Tumor-Infiltrating, mRNA cancer, Neoplasms, oncology decisions, precision oncology, Radiopharmaceuticals, T-Cell Receptor, United States Food and Drug Administration, Vaccines

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology

Insilico Medicine and Servier Announce Up to $888 Million AI-Driven Oncology R&D Collaboration

3 weeks ago talkbio0Tagged AI Platform, Drug Discovery, Insilico Medicine, Neoplasms, Pharma, Servier

Insilico Medicine; Servier; AI platform; oncology; drug discovery; Pharma.AI; $888 million

Genmab Discontinues Phase III Development of Acasunlimab Lung Cancer Asset Previously Ditched by BioNTech

3 weeks ago talkbio0Tagged acasunlimab, BioNTech, Genmab, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Phase 3, Pipeline Review

Genmab; acasunlimab; BioNTech; lung cancer; NSCLC; Phase 3; pipeline review

AbbVie Partners with China’s Zelgen on DLL3-Targeted T-Cell Engager ZG006 in Up-to-$1.2B Deal

3 weeks ago talkbio0Tagged AbbVie, Alveltamig, DLL3 gene, Small cell carcinoma of lung, T-Cell engager, Zelgen, ZG006

AbbVie; Zelgen; ZG006; Alveltamig; DLL3; T-cell engager; small cell lung cancer; licensing deal

Lunit SCOPE AI Achieves High Concordance in HER2 Assessment for Biliary Tract Cancer

3 weeks ago talkbio0Tagged Agreement, Biliary Tract Cancer, erbB-2 Receptor, Lunit SCOPE, Medical pathologist, Pathology

Lunit SCOPE; HER2; biliary tract cancer; AI pathology; concordance; pathologists

Aktis Oncology Files for IPO to Fund Lilly-Partnered Radiopharma Pipeline

1 month ago talkbio0Tagged Aktis, AKTS, AKY-1189, eli lilly, IPO, Neoplasms, Radiopharmaceuticals

Aktis Oncology; IPO; Eli Lilly; radiopharmaceuticals; AKY-1189; AKTS

Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025

1 month ago talkbio0Tagged Asymmetric Septal Hypertrophy, hematologic care, Hematologic Neoplasms, real-world evidence, Real-world Evidence, SOHO

RWE; blood cancer; real-world evidence; ASH 2025; SOHO 2025; hematologic care

FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths

1 month ago talkbio0Tagged Antibody-Drug Conjugates, Clinical Trials, Daiichi, Deruxtecan, grade 5 ILD, I-DXd, IDeate-Lung02, ifinatamab, Lung Diseases, Interstitial, Merck, Partial, Sankyo, Small cell carcinoma of lung, United States Food and Drug Administration

FDA partial clinical hold; ifinatamab deruxtecan; I-DXd; IDeate-Lung02; Merck; Daiichi Sankyo; small cell lung cancer; interstitial lung disease; grade 5 ILD; antibody-drug conjugate; clinical trial deaths

Padcev-Keytruda Combination Succeeds Again in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

1 month ago talkbio0Tagged EV-304, Event-Free Survival, KEYNOTE-B15, Keytruda, Malignant neoplasm of urinary bladder, Padcev

Padcev; Keytruda; bladder cancer; KEYNOTE-B15; EV-304; event-free survival

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

1 month ago talkbio0Tagged biobucks, Burning Mouth Syndrome, China, Clinical Trials, global strategic collaboration, Harbour BioMed, Harbour Mice ® technology, Immunology, License Agreement, milestones, multi-specific antibodies, Myers Squibb, Neoplasms

Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials